GlobalData on MSN4d
Lundbeck’s amlenetug gains orphan drug status in Japan for MSA
Amlenetug is tailored to attach to all major extracellular α-synuclein forms. The human monoclonal antibody aims to prevent ...
Pharmabiz4d
Lundbeck’ amlenetug receives Japanese orphan drug designation for treatment of multiple system atrophy
Lundbeck’ amlenetug receives Japanese orphan drug designation for treatment of multiple system atrophy: Denmark Tuesday, March 11, 2025, 11:00 Hrs [IST] H. Lundbeck A/S (Lundbec ...
H. Lundbeck A/S: Lundbeck's potential treatment for Multiple System Atrophy granted Orphan Drug Designation in Japan
The Ministry of Health, Labor, and Welfare (MHLW) in Japan has granted Orphan Drug Designation (ODD) to Lundbeck's investigational drug, amlenetug ...
PharmiWeb5d
Lundbeck’s potential treatment for Multiple System Atrophy granted Orphan Drug Designation in Japan
The Ministry of Health, Labor, and Welfare (MHLW) in Japan has granted Orphan Drug Designation (ODD) to Lundbeck’s investigational drug, amlenetug, a potential new treatment option targeting Multiple ...
Morningstar5d
Lundbeck's potential treatment for Multiple System Atrophy granted Orphan Drug Designation in Japan
VALBY, Denmark, March 10, 2025 /PRNewswire/ -- The Ministry of Health, Labor, and Welfare (MHLW) in Japan has granted Orphan Drug Designation (ODD) to Lundbeck's investigational drug, amlenetug ...